

Minutes of the Institute Biosafety Committee Meeting

January 14, 2026

Convened at: 1:00 pm and Adjourned at 2:04 pm

Present: Drs. Gelman (Chair), Foster, Gerber, Ding, McGray, Thanavala, Mr. Hartley, Ms. Holtz, Ms Keough and Mr. Korytko.

Absent: Dr Ionov and Mr. Atwal

ORSP Staff: Ms Pusateri, Ms Herter Ms. Bennett and Mr. Caruana

Guests: Mr. Flagler (potential community member) and Dr. Fang (potential member).

Meeting Place: Virtual meeting/Teams.

Minutes of December 10, 2025 were approved.

Vote: Unanimous.

Adverse Event/Accident/Incident Report

December Employee Health Service report; no incidents.

ORSP - No reports.

Old Business

1. Safety Story; this months story highlighted following procedures.
2. Laboratory inspections; May, September, October and November are pending:
 - Laboratories were visited May 15th with Dr. McGray joining the team.
 - a. Chandra level 2 lab: OES will follow up (see check list for details).
 - b. Sung level 2+ lab: OES will follow up (see check list for details).
 - Laboratories were visited September 4th with Dr. McGray joining the team:
 - a. Paragh level 2 lab: OES will follow up (see checklist for details).
 - b. Das level 2 lab: OES will follow up (see checklist for details).
 - Laboratories were visited October 9th with Dr. Ionov joining the team.
 - a. Atanassov level 2+ lab: OES will follow up (see checklist for details).
 - Laboratories were visited November 13th with Dr. McGray joining the team.
 - a. Yau level 2+ lab: OES will follow up (see checklist for details).

New Business:

1. Note; there were no January lab visits performed.
 - 3 Laboratories were visited December 4th with Dr. Ding joining the team.
 - a. Kandel BSL 2+ lab: No follow up required.
 - b. Brackett BSL2 lab: No follow up required.
 - c. Gudkov BSL2 lab: No follow up required.
 - The next inspection date will be Thursday February 5th with Dr. Thanavala joining the team
2. The administrative staff advised the committee that Key Solutions may be able to open up the left hand toolbar which would display all tabs at once (no need to navigate to a certain tab to open others). Discussed this would make reviewing applications easier. After discussion, the administrative staff will arrange with Key to have this option as soon as they can arrive at the easiest way to make the change.
3. Committee update: Dr. Foster will be stepping down from the committee. This will be her last meeting. She was thanked for her time/service. Dr. Fang was welcomed as a new member. Mr. Korytko will be stepping down as well. He was thanked for his time/service. Mr. Flagler was introduced as the potential new community member.

Protocol review:

9 Biosafety applications were reviewed.

4 Protocols referenced Virus

Application for Lab/960M: Approved pending.

Reviewed by Dr. Ding

The Continuing review/amendment application for Lab/960M, 24-11-1636 entitled: "Preclinical evaluation of novel biological therapies in immunodeficient mice engrafted with human and murine hematological malignancies." PI: Wang, Eunice was approved pending designated member review of a revised application.

The purpose of this protocol is to transduce human hematological cancer cell lines with genes involved in therapy resistance

Biosafety agents include: lentivirus

Application for Lab/1094M: Approved pending.

Reviewed by Dr. McGray

The renewal/initial Key application for Lab/1094M, 25-09-1691 entitled: "The study of CAR-T cells and multiple myeloma." PI: Olejniczak, Scott was approved pending designated member review of a revised application.

The purpose of this protocol is to study the role of PKCBII in dendritic cell differentiation, various pathways that drive multiple myeloma, and factors that maximize CAR-T functionality.

Biosafety agents include: retrovirus, lentivirus and compounds.

Application for Lab/1697M: Approved pending.

Reviewed by Dr. McGray

The Initial application for Lab/1697M, 25-11-1698 entitled: "Urolithin A Selectively Attenuates Cell Proliferation in Clear Cell Renal Cell Carcinoma through Mitophagy Induction and Augmented Mitochondrial Function: A Bench-to-Bedside Study." PI: Webster, Bradley was approved pending designated member review of a revised application.

The purpose of this protocol is to study using urolithin as a therapeutic in renal cell carcinoma.

Biosafety agents include: lentivirus

Application for Lab: Approved pending.

Reviewed by Dr. McGray

The Initial application for Lab, 25-11-1701 entitled: "Shenoy Lab." PI: Shenoy, Niraj was approved pending designated member review of a revised application.

The purpose of this protocol is to dissect genetic, genomic, immune and metabolic pathways that drive kidney cancer, and to identify and characterize regulatory factors that drive types of T-cell lymphoma.

Biosafety agents include: retrovirus, lentivirus

1 Protocol referenced gene editing

Application for lab: approved pending.

Reviewed by Dr. McGray

The Initial application for Lab, 24-02-1571 entitled: "The role of interferon signaling in the anti-cancer activity of chromatin damaging (CD) agents." PI: Gurova, Katerina was approved pending designated member review of a revised application.

The purpose of this protocol is to develop and characterize drugs that kill cancer cells via chromatin damage.

Biosafety agents include: lentivirus, doxorubicin, aclarubicin

Exempt from full committee review: None.

Amendments:

Application for Lab/11459M: Approved.

Reviewed by Dr. Gelman

The amendment to Lab based/1459M 24-09-1623 entitled: "Dr. Buxbaum Lab Biosafety -- T Cell Metabolism in Models of Cell Therapy, Transplantation, and Cancer" PI: Buxbaum, Nataliya was approved as Exempt from full committee review 12/16/2025.

Biosafety agents used include: Human CAR T Cells.

Application for Lab/1496M: Approved.

Reviewed by Dr. Gelman

The amendment to Lab based/1496M 25-01-1650 entitled: "Combining Targeted Therapies and Immunotherapy in Cancer Treatment (Experimental)" PI: Ding, Liya was approved as Exempt from full committee review 12/23/2025.

Biosafety agents used include: Cell lines and compounds.

Application for Lab/1492M: Approved.

Reviewed by Dr. Gelman

The amendment to Lab based/1492M 25-11-1702 entitled: "McLean Laboratory" PI: McLean, Karen was approved as Exempt from full committee review 12/31/2025.

Biosafety agents used include: Clarified cell line nomenclature and added cell line.

Application for Lab/1461M: Approved.

Reviewed by Dr. Gelman

The amendment to Lab based/1461M 25-07-1681 entitled: "Genetic Targeting of T Lymphocytes to Cancer Antigens for Use in Adoptive Cell Therapy" PI: Brentjens, Renier was approved as Exempt from full committee review 1/6/2026.

Biosafety agents used include: Cell lines and CAR macrophages.

See attached for complete list.

Respectfully Submitted,



Irwin Gelman, PhD
Institute Biosafety Committee Chair
Director of Research Integration; Professor of
Oncology